Drug intelligence / Profile preview

P11

Development stage: Preclinical
Lead developer: Protheragen
Modality: Peptides, Recombinant Proteins and Enzymes
Administration: Subcutaneous

Overview

P11 is an ultra-long-acting glucagon-like peptide-1 (GLP-1) receptor agonist currently in preclinical development by Protheragen. Designed as a protein therapy, P11 aims to provide sustained glycemic control for patients with type 2 diabetes by mimicking the physiological actions of endogenous GLP-1, which include stimulating insulin release, inhibiting glucagon secretion, and slowing gastric emptying. The "ultra-long-acting" designation suggests the molecule is engineered for a prolonged half-life, potentially allowing for less frequent administration compared to existing GLP-1 therapies.

Other names: Ultra-Long-Acting GLP-1 Analogue

Targets

GLP1R (GLP-1R)FCGRT (Neonatal crystallizable fragment receptor)FcγR (Low affinity immunoglobulin gamma Fc region receptor II-c)

Beyond the preview

Go deeper on P11.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on P11.

Explore the full profile